Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Marco J Haenssgen discusses the application of management thinking to solving the growing global problem of antimicrobial resistance.


Similar stories

New NDM Associate Professors

Congratulations to the following, who have now been awarded Associate Professorships:

Leveraging genetics to help inform drug target discovery

A new study led by Professor Julian Knight at the Wellcome Centre for Human Genetics and colleagues from the ULTRA-DD Consortium shows how genetics and knowledge of networks can prioritise drug targets for immune-mediated diseases.

Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies

Researchers from the University of Oxford, including NDM's Professor Simon Draper, along with partners from five institutions around the world, have identified the human antibodies that prevent the malaria parasite from entering blood cells, which may be key to creating a highly effective malaria vaccination.

Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV)

Hepatitis B virus (HBV) infects 290 million people worldwide. Oxford Nanopore Technology sequencing platforms provide potential for sequencing the whole HBV genome in a single read, facilitating improved insights into virus epidemiology, diversity, and pathogenesis.

Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus

Chikungunya virus (CHIKV) has caused explosive outbreaks in more than 60 countries. Infection can cause a long-term, debilitating disease characterised by joint inflammation and chronic arthritis lasting several years.

A Novel Vaccine Strategy Employing Serologically Different Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection

Nearly 3 million people are co-infected with hepatitis C and HIV. Effective preventive strategies targeting both viruses are needed.